Business Context and Reporting Period
Company: Calidi Biotherapeutics, Inc. (CLDI)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Calidi is a clinical-stage immuno-oncology company developing proprietary allogeneic stem cell-based and enveloped virus platforms to deliver oncolytic viruses to cancer patients. The company has no products approved for commercial sale and has not generated any revenue from product sales to date. Its primary product candidates include CLD-101 (NeuroNova platform) for high-grade glioma and CLD-201 (SuperNova platform) for solid tumors.
Key Financial Metrics
| Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(22,209) | $(29,216) |
| Operating Expenses | $(21,776) | $(28,992) |
| Research & Development | $(8,878) | $(13,008) |
| General & Administrative | $(12,898) | $(15,984) |
| Cash and Restricted Cash (End of Period) | $9,809 | $2,167 |
| Accumulated Deficit | $(121,715) | $(99,572) |
| Working Capital | $731 | $(5,929) |
Note: Working capital calculated as Total Current Assets ($10,227) minus Total Current Liabilities ($9,496) for 2024.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $7.0 million (24%) compared to 2023, primarily driven by a $4.1 million decrease in R&D expenses and a $3.1 million decrease in G&A expenses.
- Expense Drivers: The reduction in R&D was due to decreased drug manufacturing and preclinical study costs. G&A reductions were attributed to lower share-based compensation, reduced headcount, and lower legal/settlement expenses, partially offset by increased insurance costs.
- Grant Income: Grant income from the California Institute for Regenerative Medicine (CIRM) decreased significantly from $2.9 million in 2023 to $0.2 million in 2024.
- Capital Structure: The company completed multiple equity financings in 2024, including a public offering, confidentially marketed public offerings (CMPO), and an At-The-Market (ATM) offering, raising significant gross proceeds to extend its cash runway.
Guidance, Outlook, and Risks
- Going Concern: Management has concluded that there is substantial doubt about the company's ability to continue as a going concern for at least 12 months from the date of the financial statements. The company expects to continue to incur significant losses and will require substantial additional funding to support operations and clinical development.
- Clinical Outlook:
- CLD-101: Northwestern University commenced recruitment for a Phase 1b/2 clinical trial for newly diagnosed high-grade glioma in early 2025.
- CLD-201: The company filed an IND application in March 2025 and anticipates commencing a Phase 1 clinical trial for solid tumors in the first half of 2025.
- Key Risks:
- Liquidity: Insufficient cash to fund operations for the next 12 months without additional financing.
- Regulatory: Novel approach using allogeneic stem cells and oncolytic viruses creates significant regulatory challenges and uncertainty regarding approval timelines.
- Legal: Ongoing litigation involving a former Chief Accounting Officer/Interim CFO and a securities fraud complaint filed in late 2024.
- Forward Purchase Agreements: Due to the current trading price being significantly below the reset price, it is unlikely the company will receive any settlement funds from these agreements.
Important Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $9.8 million cash balance against the projected burn rate and the timeline for upcoming clinical trials (CLD-101 Phase 1b/2 and CLD-201 Phase 1).
- Financing Dilution: Review the terms of recent and subsequent equity offerings (including the March 2025 registered direct offering) to assess the dilutive impact on existing shareholders.
- Legal Contingencies: Monitor the status of the litigation involving the former CFO and the securities fraud complaint, as outcomes could result in significant financial liability or reputational damage.
- License Obligations: Confirm the company's ability to meet potential milestone payments (up to $18.7 million) and funding commitments (up to $10 million) under license agreements with Northwestern University and the University of Chicago/City of Hope.
- Manufacturing Dependencies: Assess reliance on third-party contract manufacturers, including Genscript ProBio in China, for the production of the CAL1 oncolytic virus, given potential geopolitical and regulatory risks.